



PACT – Patient New Clinical Trial and Research

Trial title	A 26-Week, Randomized, Double-Blind, Placebo-Controlled, Multi-center Study to Evaluate the Efficacy, Safety, and Tolerability of Axatilimab in Subjects with Idiopathic Pulmonary Fibrosis (IPF)
Trial synopsis	This is a Phase 2b, randomized, double-blind, placebo-controlled, multi-center study to evaluate the efficacy, safety, and tolerability of axatilimab administered through Week 26 to subjects with IPF. Patients will randomly (like flipping a coin) receive axatilimab or placebo (containing no medication) every two weeks. The effect of axatilimab on IPF will be measured through pulmonary function tests (PFTs) through by assessing patients' IPF symptoms (including breathing and cough) using standard questionnaires.
Investigational medicinal product	Axatilimab
Disease target	Idiopathic Pulmonary Fibrosis (IPF)
Sponsor	Syndax Pharmaceuticals, Inc.
Duration	Patients will participate in the study for up to 44 weeks, including an 8-week Screening Period, a 26-week Treatment Period, and a 10-week Follow-up Period that includes a Follow-up telephone call 2-weeks post final dose, and an ADA blood test Follow-up Visit 36 weeks post final dose.
Trial Status	Recruiting
Lead site(s) in Australia	Lung Research Queensland
Lead site(s) in New Zealand	
Additional sites	
Contact	pactcoordinator@cre-pf.org.au